NORTHFIELD LABORATORIES INC /DE/ - 10-Q Quarterly Report

Back to GetFilings.com

================================================================================

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED NOVEMBER 30, 2004

OR

[ ] TRANSITION REPORT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT
OF 1934

FOR THE TRANSITION PERIOD FROM _______________TO _______________

COMMISSION FILE NUMBER 0-24050

NORTHFIELD LABORATORIES INC.
(Exact name of registrant as specified in its charter)

DELAWARE 36-3378733
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification Number)

1560 SHERMAN AVENUE, SUITE 1000, EVANSTON, ILLINOIS 60201-4800
(Address of principal executive offices) (Zip Code)

REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE: (847) 864-3500

INDICATE BY CHECK MARK WHETHER THE REGISTRANT (1) HAS FILED ALL REPORTS
REQUIRED TO BE FILED BY SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF
1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS.

YES [X] NO [ ]

INDICATE BY CHECK MARK WHETHER THE REGISTRANT IS AN ACCELERATED FILER (AS
DEFINED IN RULE 12b-2 OF THE EXCHANGE ACT).
YES [X] NO [ ]

AS OF NOVEMBER 30, 2004, REGISTRANT HAD 21,551,364 SHARES OF COMMON STOCK
OUTSTANDING

================================================================================

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
INFORMATION

This Quarterly Report contains forward-looking statements concerning, among
other things, our prospects, clinical and regulatory developments affecting our
potential product and our business strategies. These forward-looking statements
are identified by the use of such terms as "intends," "expects," "plans,"
"estimates," "anticipates," "forecasts," "should," "believes" and similar terms.

These forward-looking statements involve risks and uncertainties. Actual results
may differ materially from those predicted by the forward-looking statements
because of various factors and possible events, including those discussed under
"Risk Factors" in our Annual Report on Form 10-K filed with the Securities and
Exchange Commission. Because these forward-looking statements involve risks and
uncertainties, actual results may differ significantly from those predicted in
these forward-looking statements. You should not place undue weight on these
statements. These statements speak only as of the date of this document or, in
the case of any document incorporated by reference, the date of that document.

All subsequent written and oral forward-looking statements attributable to
Northfield or any person acting on our behalf are qualified by the cautionary
statements in this section and in our Annual Report. We will have no obligation
to revise these forward-looking statements.

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors
Northfield Laboratories Inc.:

We have reviewed the balance sheet of Northfield Laboratories Inc. (a company in
the development stage) as of November 30, 2004, and the related statements of
operations for the three-month periods ended November 30, 2004 and 2003, and the
statements of operations and cash flows for the six-month periods ended November
30, 2004 and November 30, 2003, and for the period from June 19, 1985
(inception) through November 30, 2004. We have also reviewed the statements of
shareholders' equity (deficit) for the six-month period ended November 30, 2004
and for the period from June 19, 1985 (inception) through November 30, 2004.
These financial statements are the responsibility of the Company's management.

We conducted our review in accordance with standards of the Public Company
Accounting Oversight Board (United States). A review of interim financial
information consists principally of applying analytical procedures to financial
data and making inquiries of persons responsible for financial and accounting
matters. It is substantially less in scope than an audit conducted in accordance
with the standards of the Public Company Oversight Board (United States), the
objective of which is the expression of an opinion regarding the financial
statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should
be made to the financial statements referred to above for them to be in
conformity with accounting principles generally accepted in the United States of
America.

We have previously audited, in accordance with standards of the Public Company
Accounting Oversight Board (United States), the balance sheet of Northfield
Laboratories Inc. as of May 31, 2004, and the related statements of operations,
shareholders' equity (deficit), and cash flows for the year then ended and for
the period from June 19, 1985 (inception) through May 31, 2004 (not presented
herein); and in our report dated July 12, 2004, we expressed an unqualified
opinion on those financial statements. In our opinion, the information set forth
in the accompanying balance sheet as of May 31, 2004 and in the accompanying
statements of shareholders' equity (deficit) is fairly stated, in all material
respects, in relation to the statements from which it has been derived.

As discussed in note 4 to the financial statements, the Company adopted
Statement of Financial Accounting Standards No. 143, "Accounting for Asset
Retirement Obligations," as of June 1, 2003.

/s/ KPMG LLP

Chicago, Illinois
January 7, 2005

NORTHFIELD LABORATORIES INC.
(a company in the development stage)

Balance Sheets

November 30, 2004 and May 31, 2004

See accompanying notes to financial statements and accountants' review report.

NORTHFIELD LABORATORIES INC.
(a company in the development stage)

Statements of Operations

Three and six months ended November 30, 2004 and November 30, 2003 and for the
period from June 19, 1985 (inception) through November 30, 2004

See accompanying notes to financial statements and accountants' review report.

NORTHFIELD LABORATORIES INC.
(a company in the development stage)

Statements of Shareholders' Equity (Deficit)

Six months ended November 30, 2004 and for the period
from June 19, 1985 (inception) through November 30, 2004

See accompanying notes to financial statements and accountants' review report.

NORTHFIELD LABORATORIES INC.
(a company in the development stage)

Statements of Shareholders' Equity (Deficit)

Six months ended November 30, 2004 and for the period
from June 19, 1985 (inception) through November 30, 2004

See accompanying notes to financial statements and accountants' review report.

NORTHFIELD LABORATORIES INC.
(a company in the development stage)

Statements of Cash Flows

Six months ended November 30, 2004 and 2003
and for the period from June 19, 1985
(inception) through November 30, 2004

See accompanying notes to financial statements and accountants' review report.

NORTHFIELD LABORATORIES INC.
(A COMPANY IN THE DEVELOPMENT CHANGE)
NOTES TO FINANCIAL STATEMENTS
NOVEMBER 30, 2004
(UNAUDITED)

(1) BASIS OF PRESENTATION

The interim financial statements presented are unaudited but, in the opinion of
management, have been prepared in conformity with accounting principles
generally accepted in the United States of America applied on a basis consistent
with those of the annual financial statements. Such interim financial statements
reflect all adjustments (consisting of normal recurring accruals) necessary for
a fair presentation of the financial position and the results of operations for
the interim periods presented. The results of operations for the interim periods
presented are not necessarily indicative of the results to be expected for the
year ending May 31, 2005. The interim financial statements should be read in
connection with the audited financial statements for the year ended May 31,
2004.

(2) USE OF ESTIMATES

Our management has made a number of estimates and assumptions relating to the
reporting of assets and liabilities and the disclosure of contingent assets and
liabilities to prepare these financial statements in conformity with accounting
principles generally accepted in the United States of America. Actual results
could differ from those estimates.

(3) COMPUTATION OF NET LOSS PER SHARE

Basic earnings per share is based on the weighted average number of shares
outstanding and excludes the dilutive effect of unexercised common stock
equivalents. Diluted earnings per share is based on the weighted average number
of shares outstanding and includes the dilutive effect of unexercised common
stock equivalents. Because we reported a net loss for all periods presented,
basic and diluted per share amounts are the same. As of November 30, 2004, we
have 1,206,500 options and 212,392 warrants that were excluded from the net
loss per share calculation because their inclusion would have been antidilutive.

(4) ASSET RETIREMENT OBLIGATIONS

We adopted Statement of Financial Accounting Standards, SFAS No. 143 -
"Accounting for Asset Retirement Obligations" as of June 1, 2003. The cumulative
effect of the change in accounting principle upon implementation was to
recognize a net asset of $17,800, an increase in liabilities of $92,721 and an
increase in net loss of $74,921, or $0.01 per share.

The obligation relates to the restoration of a leased manufacturing facility to
its original condition. A liability of $100,000 had been recorded to the
adoption of SFAS No. 143.

Our asset retirement obligations are included in other liabilities. The balances
and changes thereto are summarized below:

If the change in accounting had been applied retroactively, our pro forma net
loss for the six months ended November 30, 2003 would have been $6,413,064, with
a $0.01 decrease in loss per share.

(5) STOCK OPTIONS

We account for our fixed plan stock options under the intrinsic value method of
accounting prescribed by Accounting Principles Board Opinion No. 25, "Accounting
for Stock Issued to Employees", and related interpretations in accounting for
options granted to directors, officers, and key employees under the plans. As
such, compensation expense is recorded on the date of grant and amortized over
the period of service only if the current market value of the underlying stock
exceeded the exercise price. No stock-based employee compensation cost is
reflected in net loss, as each option granted under these plans had an exercise
price equal to the market value of the underlying common stock on the date of
grant.

The following table illustrates the effect on net loss if we had applied the
fair value recognition provisions of Statement of Financial Accounting Standards
(SFAS) No. 123, "Accounting for Stock Based Compensation" to the measurement of
stock-based employee compensation, including a straight-line recognition of
compensation costs over the related vesting periods for fixed awards:

Recently Issued Accounting Standards

(6) In December 2004, Statement of Financial Accounting Standards (SFAS) No. 123
(Revised 2004), "Share-Based Payment: an amendment of FASB Statements No.
123 and 95", was issued. This Statement amends SFAS No. 123, "Accounting
for Stock-Based Compensation", and requires companies to recognize in the
income statement the grant-date fair value of stock options and other
equity-based compensation issued to employees. The Statement is effective
for public companies with interim or annual periods beginning after June
15, 2005. The Company will adopt SFAS 123(R) for the period ended November
30, 2005. The Company will assess the impact of the transition to this new
accounting standard during the upcoming months.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.

RECENT DEVELOPMENTS

We are currently enrolling patients in a pivotal Phase III trial in which
PolyHeme is being used for the first time in civilian, urban trauma settings to
treat severely injured patients in hemorrhagic shock before they reach the
hospital. Under this protocol, treatment with PolyHeme begins at the scene of
the injury or in the ambulance and continues during transport and the initial 12
hour post-injury period in the hospital. Since blood is not presently carried in
ambulances, the use of PolyHeme in this setting has the potential to improve
survival and address a critical, unmet medical need.

As of January 10, 2005, 16 clinical sites in the United States were
enrolling patients in our pivotal Phase III trial and two other sites had
received final Institutional Review Board approval and were preparing to begin
patient enrollment. Eight additional sites were engaged in the pre-trial public
disclosure and community consultation process. Each of the sites participating
in the trial is designated as a Level I trauma center because of its capacity to
treat the most severely injured trauma patients. We anticipate that a total of
approximately 25 or more clinical sites across the United States will eventually
participate in the trial. The trial has an expected enrollment of 720 patients.

As part of our trial protocol, an independent data monitoring committee,
or IDMC, consisting of independent medical and biostatistical experts is
responsible for periodically evaluating the safety data from the trial and
making recommendations relating to the continuation or modification of the trial
protocol to minimize any identified risks to patients. The protocol includes
four planned evaluations by the IDMC that occur after 60, 120, 250 and 500
patients have been enrolled and monitored for a 30-day follow up period. The
IDMC will focus its initial review on mortality and serious adverse events and
will review all safety data as the trial continues. We will receive a
recommendation from the IDMC after each review, but we will not have access to
the trial data reviewed by the IDMC until the trial is completed.

In July 2004, the IDMC recommended that our trial continue without
modification based on the committee's initial review of blinded data on
mortality and serious adverse events from the evaluation of the first 60
patients enrolled in the trial. The IDMC again recommended continuation of the
trial without modification in October 2004 based on its review of data following
enrollment of the first 120 patients. The length of time for completion of the
IDMC review after each enrollment target is reached is expected to become longer
as the number of enrolled patients increases. Enrollment in the trial continues
during the period of 30 day follow-up, the data preparation and analysis, and
the actual IDMC meeting, so the disclosure of the IDMC recommendation does not
correspond to the current status of patient enrollment. We anticipate that the
IDMC will complete its third review of trial data on the first 250 patients
enrolled in our trial in the second calendar quarter of 2005. Northfield's
current goal is to complete the patient enrollment phase of our trial by the end
of calendar 2005. Our ability to achieve this goal will depend, in part, on the
number of clinical sites participating in our trial, and the ability of these
sites to enroll patients at the projected rates.

The progress of our pivotal Phase III trial and the timing and outcome of
the FDA review process are subject to significant risks and uncertainties, many
of which are outside of our control. We urge you review the "Risk Factors"
section in our most recent Annual Report on Form 10-K filed with the Securities
and Exchange Commission for a discuss of certain of these risks and
uncertainties.

Since Northfield's incorporation in 1985, we have devoted substantially
all of our efforts and resources to the research, development and clinical
testing of our potential product, PolyHeme(R). We have incurred operating losses
during each year of our operations since inception and expect to incur
substantial additional operating losses for the next several years. From
Northfield's inception through November 30, 2004, we have incurred operating
losses totaling $134,838,000.

We will be required to complete our pivotal Phase III trial and obtain
regulatory approval from Food and Drug Administration before PolyHeme can be
sold commercially. The FDA regulatory process is subject to significant risks
and uncertainties, including those described under "Risk Factors" in our annual
report on Form 10-K filed with the Securities and Exchange Commission. We
therefore cannot at this time reasonably estimate the timing of any future
revenues from the commercial sale of PolyHeme. The costs incurred by Northfield
to date and during each period presented below in connection with our
development of PolyHeme are described in the Statements of Operations in our
financial statements.

Our success will depend on several factors, including our ability to
obtain FDA regulatory approval of PolyHeme and our manufacturing facilities,
obtain sufficient quantities of blood to manufacture PolyHeme in commercial
quantities, manufacture and distribute PolyHeme in a cost-effective manner,
enforce our patent positions and raise sufficient capital to fund these
activities. We have experienced significant delays in the development and
clinical testing of PolyHeme. We cannot ensure that we will be able to achieve
these goals or that we will be able to realize product revenues or profitability
on a sustained basis or at all.

RESULTS OF OPERATIONS

We reported no revenues for either of the three and six-month periods
ended November 30, 2004 or 2003. From Northfield's inception through November
30, 2004, we have reported total revenues of $3,000,000, all of which were
derived from licensing fees.

OPERATING EXPENSES

Operating expenses for our second fiscal quarter ended November 30, 2004
totaled $5,088,000, an increase of $1,508,000 from the $3,580,000 reported in
the second quarter of fiscal 2004. Measured on a percentage basis, fiscal 2005
operating expenses exceeded fiscal 2004 expenses by 42.1%. As expected,
significant increases in operating expenses were incurred to conduct, expand,
report and support our pivotal Phase III trial.

Research and development expense during the second quarter of fiscal 2005
totaled $4,177,000, an increase of $1,619,000, or 63.3%, from the $2,558,000
reported in the second quarter of fiscal 2004. Our pivotal Phase III trial is
enrolling patients and we continue to actively pursue additional Level I trauma
sites to participate. As of November 30, 2004, 16 sites had full Institutional
Review Board approval and were enrolling patients. Work continues to achieve our
goal of having 20 to 25 sites enrolling patients by Spring 2005. Included in the
second quarter of fiscal 2005 research and development expense was an increase
of $1,385,000 for clinical site charges and for data accumulation, data
monitoring and analysis compared to the second quarter of fiscal 2004. We
anticipate that these expenses will continue to grow consistent with the rate of
patient enrollment and site initiation. Also included in the second quarter
research and development expenses was an increased use of science consultants to
prepare for the reporting to FDA.

General and administrative expenses in the second quarter of fiscal 2005
totaled $910,000, which is a decrease of $112,000, or 11.0%, from the general
and administrative expenses reported in the second quarter of fiscal 2004 of
$1,022,000. The decreased expense in the second quarter of fiscal 2005 compared
to the second quarter of fiscal year 2004 was due to a reduced use of
professional services and administrative consulting. We anticipate modest
increases in general and administrative expenses over the balance of fiscal
2005. Our new Internet Web site was launched in September 2004 and an expansion
of business development activities is planned. Successfully completing our
pivotal Phase III trial remains our primary focus.

For the six-month period ended November 30, 2004, operating expenses of
$10,075,000 exceeded the operating expenses of $6,462,000 incurred in the
six-month period ended November 30, 2003. The dollar increase was $3,613,000 and
the percentage increase equaled 55.9%. The increases can primarily be attributed
to the planning, preparation, execution, analysis and reporting of our pivotal
Phase III trial.

Research and development expenses for the six-month period ended November
30, 2004 totaled $8,216,000, which represents a $3,459,000, or 72.7%, increase
from the comparable expenses incurred in the six-month period ended November 30,
2003. During the current fiscal year, increased expense totalling $2,744,000 was
reported for sites in monitoring related activities. Additional expenses were
also recorded to manufacture increased quantities of clinical material. The cost
of additional personnel and higher benefit costs also added to the current year
expenses.

General and administrative expenses for the six-month period ended
November 30, 2004 totaled $1,859,000, which is an increase of $155,000, or 9.1%,
from the general and administrative expenses reported for the six-month period
ended November 30, 2003 of $1,704,000. The increased expenses this fiscal year
are

due to taxes payable on our increased market capitalization and expenses related
to preparing for commercialization. We anticipate modest increases in general
and administrative expenses over the balance of fiscal 2005 as successfully
completing our pivotal Phase III trial remains our primary focus.

INTEREST INCOME

Interest income for the three-month period ended November 30, 2004 totaled
$156,000, an increase of $131,000 from the $25,000 in interest income reported
in the three-month period ended November 30, 2003. Following three successful
fund raising efforts in fiscal 2004, Northfield started the fiscal year 2005
with $42,487,000 in available cash resources. This compares to available cash
resources at the beginning of fiscal 2004 of $6,890,000. The significant
increase in cash balances and a modest increase in available short-term interest
rates caused interest income to increase.

Interest income for the six-month period ended November 30, 2004 totaled
$276,000, an increase of $228,000 from the $48,000 in interest income reported
in the six-month period ended November 30, 2003. The increase in cash balances
and a modest increase in available short-term interest rates caused interest
income to increase. We continue to invest our funds only in high grade,
short-term instruments.

NET LOSS

The net loss for the three-month period ended November 30, 2004 totaled
$4,932,000, or $0.23 per share, compared to a net loss of $3,555,000, or $0.22
per share, for the three-month period ended November 30,

2003. In dollar terms the loss increased by 38.7%, primarily from the expense of
conducting our pivotal Phase III trial. However, on a per share basis the
additional 5,277,000 shares outstanding in the current year mitigated the loss
per share increase to 4.5%.

On a fiscal year to date basis, we reported a loss of $9,799,000 or $0.46
per share compared to a prior year six-month loss of $6,488,000 or $0.42 per
share. The increased net loss of $3,311,000, primarily from the expense of
conducting our pivotal Phase III trial in the first six-months of the current
fiscal year as compared to the same period in the prior year was mitigated by
the increased number of shares outstanding in the current fiscal year.

LIQUIDITY AND CAPITAL RESOURCES

From Northfield's inception through November 30, 2004, we have used cash
in operating activities and for the purchase of property, plant, equipment and
engineering services in the amount of $132,525,000. For the six-months ended
November 30, 2004 and 2003, these cash expenditures totaled $10,129,000 and
$6,779,000, respectively. The six-month increase in cash utilization is due
primarily to expenses related to our pivotal Phase III trial.

We have financed our research and development and other activities to date
through the public and private sale of equity securities and, to a more limited
extent, through the license of product rights. As of November 30, 2004, we had
cash and marketable securities totaling $33,854,000. It should be noted that in
this fiscal year lobbying efforts have been successful in securing a $1.4
million federal appropriation as part of the 2005 Defense Appropriation Bill. As
of November 30, 2004 we have not yet received the funds.

We believe our existing capital resources will be adequate to satisfy our
operating capital requirements, including patient enrollment and the initial
data accumulation for our pivotal Phase III trial, and maintain our existing
manufacturing plant and office facilities for approximately the next 15 to 18
months. Thereafter, we will require substantial additional funding to pursue FDA
regulatory approval for Polyheme, to expand our commercial manufacturing and
marketing capabilities and to continue our ongoing operations.

We may issue additional equity or debt securities or enter into
collaborative arrangements with strategic partners, which could provide us with
additional funding or absorb expenses we would otherwise be required to pay. We
are also pursuing potential sources of additional government funding. Any one or
a combination of these sources may be utilized to raise additional capital. We
believe our ability to raise additional capital or enter into a collaborative
arrangement with a strategic partner will depend primarily on the results of our
clinical trial, as well as general conditions in the business and financial
markets. An inability to raise sufficient levels of capital could materially
delay or prevent the commercialization of PolyHeme, even if approved by FDA.

Our capital requirements may vary materially from those now anticipated
because of the timing and results of our clinical testing of PolyHeme, the
establishment of relationships with strategic partners, changes in the scale,
timing or cost of our commercial manufacturing facility, competitive and
technological advances, the FDA regulatory process, changes in our marketing and
distribution strategy and other factors.

CRITICAL ACCOUNTING POLICIES

The preparation of financial statements requires management to make
estimates and assumptions that affect amounts reported therein. We believe the
following critical accounting policy reflects our more significant judgments and
estimates used in the preparation of our financial statements.

NET DEFERRED TAX ASSETS VALUATION

We record our net deferred tax assets in the amount that we expect to
realize based on projected future taxable income. In assessing the
appropriateness of our valuation, assumptions and estimates are required, such
as Northfield's ability to generate future taxable income. In the event we were
to determine that it was more likely than not we would be able to realize our
deferred tax assets in the future in excess of their carrying value, an
adjustment to recognize the deferred tax assets would increase income in the
period such determination was made. As of November 30, 2004, we have recorded a
100% percent valuation allowance against our net deferred tax assets.

CONTRACTUAL OBLIGATIONS

The following table reflects a summary of our contractual cash obligations
as of November 30, 2004:

- ----------
(1) The lease for our Evanston headquarters is cancelable with six months
notice combined with a termination payment equal to six months base rent.
At November 30, 2004, this penalty would have amounted to $156,750.

Recently Issued Accounting Standards

In December 2004, Statement of Financial Accounting Standards (SFAS) No. 123
(Revised 2004), "Share-Based Payment: an amendment of FASB Statements No.
123 and 95", was issued. This Statement amends SFAS No. 123, "Accounting
for Stock-Based Compensation", and requires companies to recognize in the
income statement the grant-date fair value of stock options and other
equity-based compensation issued to employees. The Statement is effective
for public companies with interim or annual periods beginning after June
15, 2005. The Company will adopt SFAS 123(R) for the period ended November
30, 2005. The Company will assess the impact of the transition to this new
accounting standard during the upcoming months.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

We currently do not have any foreign currency exchange risk. We invest our
cash and cash equivalents in government securities, certificates of deposit and
money market funds. These investments are subject to interest rate risk.
However, due to the nature of our short-term investments, we believe that the
financial market risk exposure is not material. A one percentage point decrease
on our cash and marketable securities of $33.8 million at November 30, 2004
would decrease interest income by $338,000 on an annual basis.

ITEM 4. CONTROLS AND PROCEDURES.

Based on their evaluation as of the end of the period covered by this
report, our Chief Executive Officer and Senior Vice President and Chief
Financial Officer have concluded that Northfield's disclosure controls and
procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities
Exchange Act of 1934, are effective to ensure that information required to be
disclosed by us in the reports that we file or submit under the Securities
Exchange Act is recorded, processed, summarized and reported within the time
periods specified in the Securities and Exchange Commission's rules and forms.
There were no changes in our internal control over financial reporting that
occurred during our most recent fiscal quarter that have materially affected, or
are reasonably likely to materially affect, our internal control over financial
reporting.

PART II. OTHER INFORMATION

Item 6. Exhibits

a) Exhibit 10.1 - Form of restricted stock grant to officers and
employees pursuant the Northfield Laboratories
Inc. 2003 Equity Compensation Plan

Exhibit 10.2 - Form of stock option grant to officers and
employees pursuant the Northfield Laboratories
Inc. 2003 Equity Compensation Plan

Exhibit 10.3 - Form of stock option grant to directors pursuant
the Northfield Laboratories Inc. 2003 Equity
Compensation Plan.

Exhibit 10.4 - Form of stock option grant pursuant the
Northfield Laboratories Inc. Stock Option Plan
for New Employees

Exhibit 15 - Acknowledgment of Independent Registered Public
Accounting Firm Regarding Accountants' Review
Report

Exhibit 31.1 - Certification of Steven A. Gould, M.D., pursuant
to Rule 13a-14(a) under the Securities Exchange
Act of 1934

Exhibit 31.2 - Certification of Jack J. Kogut, pursuant to Rule
13a-14(a) under the Securities Exchange Act of
1934

Exhibit 32.1 - Certification of Steven A. Gould, M.D., pursuant
to 18 U.S.C. Section 1350, as adopted pursuant
to Section 906 of the Sarbanes-Oxley Act of 2002

Exhibit 32.2 - Certification of Jack J. Kogut, pursuant to 18
U.S.C. Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002

b) None

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this
report has been signed below by the following persons on behalf of the Company
in the capacities indicated on January 7, 2005.

SIGNATURE TITLE

/s/ Steven A. Gould, M.D. Chairman of the Board and Chief
- ------------------------- Executive Officer (Principal
Steven A. Gould, M.D. Executive Officer)

/s/ Jack J. Kogut Sr. Vice President and Chief
- ------------------------- Financial Officer
Jack J. Kogut